Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Solomon

Showing results (851-860 of 900) with videos related to

Pageof 90
Sort By:
American Journal of Human Genetics|May 6, 2017
Systematic Computational Identification of Variants That Activate Exonic and Intronic Cryptic Splice SitesMelissa Lee, Patrick Roos, Neeraj Sharma, et al.
Annals of the American Thoracic Society|June 11, 2026
Elexacaftor-Tezacaftor-Ivacaftor for Individuals with Residual CFTR Activity: An Open-Label, Nonrandomized Clinical TrialRachel W Linnemann, George M Solomon, Adrianna L Westbrook, et al.
The Journal of Neuropsychiatry and Clinical Neurosciences|August 20, 2016
Cognitive Reserve as a Modifier of Clinical Expression in Chronic Traumatic Encephalopathy: A Preliminary ExaminationMichael L Alosco, Jesse Mez, Neil W Kowall, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 3, 2016
Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapyE Ben-Ami, C M Barysauskas, M von Mehren, et al.
Plos One|March 2, 2013
Mycobacterium abscessus induces a limited pattern of neutrophil activation that promotes pathogen survivalKenneth C Malcolm, E Michelle Nichols, Silvia M Caceres, et al.
Physical Review Letters|November 13, 2008
Intense geodesic acousticlike modes driven by suprathermal ions in a tokamak plasmaR Nazikian, G Y Fu, M E Austin, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 30, 2026
Longitudinal changes in bone mineral density after initiation of elexacaftor-tezacaftor-ivacaftor in youth and adults with cystic fibrosis: PROMISE-ENDOMeghan Shirley Bezerra, Babette S Zemel, Robert J Gallop, et al.
The Journal of Clinical Endocrinology and Metabolism|December 10, 2024
Glycemia and Insulin Secretion in Cystic Fibrosis Two Years After Elexacaftor/Tezacaftor/Ivacaftor: PROMISE-ENDOChristine L Chan, Meghan Shirley Bezerra, Darko Stefanovski, et al.
The British Journal of Surgery|August 14, 2020
International variation in managing locally advanced or recurrent rectal cancer: prospective benchmark analysisQ Denost, M Solomon, J-J Tuech, et al.
The Lancet. Respiratory Medicine|August 29, 2024
Evaluation of elexacaftor-tezacaftor-ivacaftor treatment in individuals with cystic fibrosis and CFTR<sup>N1303K</sup> in the USA: a prospective, multicentre, open-label, single-arm trialGeorge M Solomon, Rachel W Linnemann, Rachel Rich, et al.
Pageof 90

Showing results (851-860 of 900) with videos related to

Sort By:
Pageof 90
American Journal of Human Genetics|May 6, 2017
Systematic Computational Identification of Variants That Activate Exonic and Intronic Cryptic Splice SitesMelissa Lee, Patrick Roos, Neeraj Sharma, et al.
Annals of the American Thoracic Society|June 11, 2026
Elexacaftor-Tezacaftor-Ivacaftor for Individuals with Residual CFTR Activity: An Open-Label, Nonrandomized Clinical TrialRachel W Linnemann, George M Solomon, Adrianna L Westbrook, et al.
The Journal of Neuropsychiatry and Clinical Neurosciences|August 20, 2016
Cognitive Reserve as a Modifier of Clinical Expression in Chronic Traumatic Encephalopathy: A Preliminary ExaminationMichael L Alosco, Jesse Mez, Neil W Kowall, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 3, 2016
Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapyE Ben-Ami, C M Barysauskas, M von Mehren, et al.
Plos One|March 2, 2013
Mycobacterium abscessus induces a limited pattern of neutrophil activation that promotes pathogen survivalKenneth C Malcolm, E Michelle Nichols, Silvia M Caceres, et al.
Physical Review Letters|November 13, 2008
Intense geodesic acousticlike modes driven by suprathermal ions in a tokamak plasmaR Nazikian, G Y Fu, M E Austin, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 30, 2026
Longitudinal changes in bone mineral density after initiation of elexacaftor-tezacaftor-ivacaftor in youth and adults with cystic fibrosis: PROMISE-ENDOMeghan Shirley Bezerra, Babette S Zemel, Robert J Gallop, et al.
The Journal of Clinical Endocrinology and Metabolism|December 10, 2024
Glycemia and Insulin Secretion in Cystic Fibrosis Two Years After Elexacaftor/Tezacaftor/Ivacaftor: PROMISE-ENDOChristine L Chan, Meghan Shirley Bezerra, Darko Stefanovski, et al.
The British Journal of Surgery|August 14, 2020
International variation in managing locally advanced or recurrent rectal cancer: prospective benchmark analysisQ Denost, M Solomon, J-J Tuech, et al.
The Lancet. Respiratory Medicine|August 29, 2024
Evaluation of elexacaftor-tezacaftor-ivacaftor treatment in individuals with cystic fibrosis and CFTR<sup>N1303K</sup> in the USA: a prospective, multicentre, open-label, single-arm trialGeorge M Solomon, Rachel W Linnemann, Rachel Rich, et al.
Pageof 90